Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 150

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4A
Chunk 150
---
 we refer to in this annual report with the understanding that our actual results in the future
may be materially different from or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements.
Other sections of this annual report include additional factors which could adversely affect our business and financial performance. Moreover,
we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management
to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any
factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth
in “ Item 3. Key Information - D. Risk Factors” and elsewhere in this annual report. We caution you that our businesses
and financial performance are subject to substantial risks and uncertainties.

The forward-looking statements
made in this annual report relate only to events or information as of the date on which these statements are made in this annual report.
We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or
otherwise, after the date of this annual report. You should not rely upon forward-looking statements as predictions of future events.

A. Operating Results

Overview

We are a clinical stage biopharmaceutical
company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through
the co-development of PathsDxTest, a novel molecular-based rapid pathogen identification and detection diagnostics technology,
with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.

The Company now focuses all of its efforts on R& D and therefore
no longer performs any therapeutic services. While the Company may commence therapeutic services in the future, as of December 31, 2024
and the date hereof, it only operates in one segment.

Based on our evaluation of
preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential
market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting
Lead Projects is not based on any mechanical formula